A tumor-penetrating peptide modification enhances the antitumor activity of endostatin in vivo

Anti-Cancer Drugs

Volumn 22, Issue 5, 2011, Pages 409-415

  Zhang, Hai Tao ^a,b   Li, Hui Cheng ^b   Li, Zheng Wu ^b   Guo, Chang Hong ^a  

^a HARBIN NORMAL UNIVERSITY   (China)

^b Harbin Pharmaceutical Group RandD Center   (China)

Author keywords

Angiogenesis; antiangiogenesis; endostatin; endothelial cell; integrin; RGD ligands; tumor targeting

Indexed keywords

ENDOSTATIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GROWTH; CONTROLLED STUDY; DRUG INHIBITION; DRUG MECHANISM; FEMALE; HUMAN; HUMAN CELL; LIVER CANCER; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN MODIFICATION;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; BASE SEQUENCE; CAPILLARY PERMEABILITY; CATTLE; CELL MOVEMENT; CELL PROLIFERATION; CELL-PENETRATING PEPTIDES; CHICK EMBRYO; ENDOSTATINS; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; INTEGRINS; LIVER NEOPLASMS; MICE; MICE, NUDE; MOLECULAR SEQUENCE DATA; OLIGOPEPTIDES; PROTEIN BINDING; RECOMBINANT FUSION PROTEINS;

EID: 79955058638     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/CAD.0b013e328342050d     Document Type: Article

References (23)

1. Folkman J. Antiangiogenesis in cancer therapy: endostatin and its mechanisms of action. Exp Cell Res 2006; 312:594-607. (Pubitemid 43290336)
2. Rehn M, Veikkola T, Kukk-Valdre E, Nakamura H, Ilmonen M, Lombardo C, et al. Interaction of endostatin with integrins implicated in angiogenesis. Proc Natl Acad Sci USA 2001; 98:1024-1029. (Pubitemid 32121180)
3. Sorensen DR, Read TA, Porwol T, Olsen BR, Timpl R, Sasaki T, et al. Endostatin reduces vascularization, blood flow and growth in a rat gliosarcoma. Neuro Oncol 2002; 4:1-8. (Pubitemid 34269461)
4. O'Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 1997; 88:277-285. (Pubitemid 28015876)
5. Sudhakar A, Sugimoto H, Yang C, Lively J, Zeisberg M, Kalluri R. Human tumstatin and human endostatin exhibit distinct antiangiogenic activities mediated by avb3 and a5b1 integrins. Proc Natl Acad Sci USA 2003; 100:4766-4771. (Pubitemid 36457804)
6. Wickstrom SA, Alitalo K, Keski-Oja J. Endostatin associates with integrin a5b1 and caveolin-1, and activates Src via a tyrosyl phosphatase-dependent pathway in human endothelial cells. Cancer Res 2002; 62:5580-5589.
7. Desgrosellier JS. Integrins in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer 2010; 10:9-22.
8. Sugahara KN, Teesalu T, Karmali PP, Kotamraju VR, Agemy L, Girard OM, et al. Tissue-penetrating delivery of compounds and nanoparticles into tumors. Cancer Cell 2009; 16:510-520.
9. Teesalu T, Sugahara KN, Kotamraju VR, Ruoslahti E. C-end rule peptides mediate neuropilin-1-dependent cell, vascular, and tissue penetration. Proc Natl Acad Sci USA 2009; 106:16157-16162.
10. Minchinton AI, Tannock IF. Drug penetration in solid tumours. Nat Rev Cancer 2006; 6:583-592. (Pubitemid 44140857)
11. Ruoslahti E. Specialization of tumour vasculature. Nat Rev Cancer 2002; 2:83-90. (Pubitemid 37328795)
12. Dhanabal M, Volk R, Ramchandran R, Simons M, Sukhatme VP. Cloning, expression, and in-vitro activity of human endostatin. Biochem Biophys Res Commun 1990; 258:345-352.
13. Folkman J, Merler E, Abemathy C, Williams G. Isolation of tumor factor responsible for angiogenesis. J Exp Med 1971; 133:275-288.
14. Arap W, Pasqualini R, Ruoslahti E. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science 1998; 279:377-380. (Pubitemid 28063372)
15. Dhanabal M, Ramchandran R, Volk R, Stillman IE, Lombardo M, Iruela-Arispe ML, et al. Endostatin: yeast production, mutants, and antitumor effect in renal cell carcinoma. Cancer Res 1999; 59:189-197. (Pubitemid 29062977)
16. Pellet-Many C, Frankel P, Jia H, Zachary I. Neuropilins: structure, function and role in disease. Biochem J 2008; 411:211-226. (Pubitemid 351580173)
17. Temming K, Schiffelers RM, Molema G, Kok RJ. RGD-based strategies for selective delivery of therapeutics and imaging agents to the tumour vasculature. Drug Resist Updat 2005; 8:381-402. (Pubitemid 43358061)
18. Yokoyama Y, Ramakrishnan S. Addition of integrin binding sequence to a mutant human endostatin improves inhibition of tumor growth. Int J Cancer 2004; 111:839-848. (Pubitemid 39096232)
19. Weide T, Modlinger A, Kessler H. Spatial screening for the identification of the bioactive conformation of integrin ligands. Top Curr Chem 2007; 272: 1-50.
20. Hoffman JA, Giraudo E, Singh M, Zhang L, Inoue M, Porkka K, et al. Progressive vascular changes in a transgenic mouse model of squamous cell carcinoma. Cancer Cell 2003; 4:383-391. (Pubitemid 37491099)
21. Joyce JA, Laakkonen P, Bernasconi M, Bergers G, Ruoslahti E, Hanahan D. Stage-specific vascular markers revealed by phage display in a mouse model of pancreatic islet tumorigenesis. Cancer Cell 2003; 4:393-403. (Pubitemid 37491100)
22. Laakkonen P, Porkka K, Hoffman JA, Ruoslahti E. A tumor-homing peptide with a targeting specificity related to lynphatic vessels. Nat Med 2002; 8:751-755. (Pubitemid 34778730)
23. Hambley TW, Hait WN. Is anticancer drug development heading in the right direction? Cancer Res 2009; 69:1259-1262.